We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
RANDOX LABORATORIES

Download Mobile App




Semen Exosome MicroRNA Proves Biomarker for Prostate Cancer

By LabMedica International staff writers
Posted on 07 Oct 2019
Print article
Image: Micrograph of a prostate biopsy showing normal prostatic glands and glands of prostate cancer (prostatic adenocarcinoma) (Photo courtesy of Wikimedia Commons).
Image: Micrograph of a prostate biopsy showing normal prostatic glands and glands of prostate cancer (prostatic adenocarcinoma) (Photo courtesy of Wikimedia Commons).
Researchers have shown that microRNAs present in semen exosomes can serve as biomarkers for the non-invasive diagnosis of prostate cancer.

Exosomes are a type of extracellular vesicle (EV), a class that also includes microvesicles and apoptotic bodies. EVs are cell-derived lipid-bilayer-enclosed structures, with sizes ranging from 30 to 5,000 nanometers. In the past decade, EVs have emerged as important mediators of cell communication because they serve as vehicles for the intercellular transmission of biological signals (proteins or nucleic acids) capable of altering cell function and physiology.

MicroRNAs (miRNAs) and short interfering RNAs (siRNA) comprise a class of about 20 nucleotides-long RNA fragments that block gene expression by attaching to molecules of messenger RNA in a fashion that prevents them from transmitting the protein synthesizing instructions they had received from the DNA. MiRNAs resemble siRNAs of the RNA interference (RNAi) pathway, except miRNAs derive from regions of RNA transcripts that fold back on themselves to form short hairpins, whereas siRNAs derive from longer regions of double-stranded RNA. With their capacity to fine-tune protein expression via sequence-specific interactions, miRNAs help regulate cell maintenance and differentiation. Furthermore, miRNAs play essential roles in tumor development, are stable under diverse analytical conditions, and can be readily detected in body fluids.

Although it is specific for prostate tissue, serum prostate-specific antigen (PSA) screening has resulted in an over-diagnosis of prostate cancer and many unnecessary biopsies of benign disease due to a well-documented low cancer specificity. Therefore, improved diagnostic methods are required.

In this regard, investigators at the Bellvitge Biomedical Research Institute (Barcelona, Spain) suggested that semen could be considered a liquid biopsy of the organs of male reproductive system and specifically of prostate gland, since approximately 40% of semen is derived from prostatic tissue, so that its contents are most likely to contain prostate disease-specific derived molecules.

To test this theory, the investigators profiled the expression level of miRNAs contained in semen exosomes from men with moderately increased PSA levels to assess their usefulness, either alone or in addition to PSA marker, as non-invasive biomarkers for the early efficient diagnosis and prognosis of prostate cancer.

The investigators reported that an altered miRNA expression pattern was detected by high throughput profiling analysis of prostate cancer patients when compared with healthy individuals’exosomal semen samples. The presence of vasectomy was taken into account for the interpretation of results. Fourteen miRNAs were selected for miRNA validation as prostate cancer biomarkers in a subsequent set of semen samples. The pathway analysis of predicted miRNA target genes supported a role for these miRNAs in prostate cancer diagnosis and/or progression.

"Our study shows semen exosome miRNA-based models as molecular biomarkers with the potential to improve prostate cancer diagnosis/prognosis efficiency. These miRNA-based tests should provide reliable information that will help physicians to take clinical decisions as well as will save unnecessary invasive biopsies to the patients, improving the efficiency of detection of prostate cancer and patient outcome," said senior author Dr. Sara Larriba, a principle investigator at the Bellvitge Biomedical Research Institute. "Our aim is to offer our results to the clinics as a diagnostic test. In that respect, as our next step, we should carry out further prospective studies on larger cohorts of patients before this miRNA-based biomarker could be adopted in the daily clinical practice."

The semen exosome study was published in the September 24, 2019, online edition of the journal Scientific Reports.

Related Links:
Bellvitge Biomedical Research Institute

Gold Supplier
Auto Urinary Sediment Analyzer
EH-2030
New
Silver Supplier
Real-Time PCR Thermal Cycler
Eonis Q96
New
Automated Sample Preparation System
ASPEC 241
New
Radiotherapy Toxicity Measurement Assay
Radiotherapy Toxicity Measurement Assay

Print article

Channels

Clinical Chem.

view channel
Image: Brief schematic diagram of the detection principle and method (Photo courtesy of CAS)

Rapid, Non-Invasive Method Diagnoses Type 2 Diabetes by Sniffing Urinary Acetone

Over 90% of diabetes cases are attributed to Type 2 diabetes (T2D), a prevalent metabolic condition that is expected to impact 380 million individuals globally by 2025. Despite being highly accurate, the... Read more

Molecular Diagnostics

view channel
Image: Researchers have identified the origin of subset of autoantibodies that worsen lupus (Photo courtesy of Pexels)

Lupus Biomarker Testing Could Help Identify Patients That Need Early and Aggressive Treatment

Systemic lupus erythematosus (SLE) is an autoimmune disease that occurs when the body's antibodies, which usually protect against infections, attack healthy cells and proteins. These autoantibodies can... Read more

Immunology

view channel
Image: A genetic test could guide the use of cancer chemotherapy (Photo courtesy of Pexels)

Genetic Test Predicts Whether Bowel Cancer Patients Can Benefit From Chemotherapy

Late-stage bowel cancer patients usually undergo a series of chemotherapies and targeted medicines for cancer treatment. However, the responses to the last-line chemotherapy treatment trifluridine/tipiracil... Read more

Microbiology

view channel
Image: Use of DBS samples can break barriers in hepatitis C diagnosis and treatment for populations at risk (Photo courtesy of Pexels)

DBS-Based Assay Effective in Hepatitis C Diagnosis and Treatment for At Risk Populations

In a bid to eliminate viral hepatitis as a public health threat by 2030, the World Health Organization (WHO) has put forth a proposed strategy. To this end, researchers at the Germans Trias i Pujol Research... Read more

Pathology

view channel
Image: New research has opened a path for fast and accurate cancer diagnosis (Photo courtesy of Imagene)

AI-Based Image Analysis Software Profiles Cancer Biomarkers in Real Time

Lung cancer is the most widespread type of cancer worldwide, resulting in approximately 1.76 million fatalities annually. Non-small cell lung cancer (NSCLC) accounts for 85% of all lung cancer diagnoses... Read more

Technology

view channel
Image: Live view of non-fluorescent specimens using the glowscope frame (Photo courtesy of Winona State University)

Device Converts Smartphone into Fluorescence Microscope for Just USD 50

Fluorescence microscopes are utilized to examine specimens labeled with fluorescent stains or expressing fluorescent proteins, like those tagged with green fluorescent protein. However, since these microscopes... Read more

Industry

view channel
Image: The global antimicrobial resistance diagnostics market size is expected to reach USD 5.7 billion by 2028 (Photo courtesy of Pexels)

Global Antimicrobial Resistance Diagnostics Market Driven by Increasing Hospital-Acquired Infections

Antimicrobial drugs are intended to counteract the harmful effects of microbes and promote a healthy life. However, their excessive use can result in the development of resistance, commonly referred to... Read more
Copyright © 2000-2023 Globetech Media. All rights reserved.